Latest news with #ADMA
Mid East Info
2 days ago
- Business
- Mid East Info
Sharjah Self-Defence takes lead in fifth round opener of Khaled bin Mohamed bin Zayed Jiu-Jitsu Championship
Al Ain Jiu-Jitsu Clun in second place, followed by ADMA in third Dubai, August, 2025 : The fifth round of the second edition of the Khaled bin Mohamed bin Zayed Jiu-Jitsu Championship (no-gi) kicked off today (Saturday) at Al Nasr Club in Dubai, attracting wide participation from athletes representing clubs and academies across the UAE. At the end of the opening day, Sharjah Self-Defence Sports Club topped the standings, followed by Al Ain Jiu-Jitsu Club in second place and ADMA in third. The first day featured strong competition in the under-12, under-14, and under-16 categories. Athletes demonstrated high technical levels, quick reactions, and precise execution to amass points under the championship's classification system, designed to ensure fairness and reinforce competitiveness among players and clubs. The day's competitions were attended by H.E. Yousef Abdullah Al Batran, Board Member of the UAE Jiu-Jitsu Federation; H.E. Mishal Abdulkarim Julfar, CEO of the Dubai Corporation for Ambulance Services; Fawzia Faridoon, Acting Director of Sports Events Department at Dubai Sports Council; Amina Ahmed, Branch Manager of Abu Dhabi Islamic Bank in Muhaisnah; Fahad Al Marzouqi, Branch Manager of Abu Dhabi Islamic Bank in Deira; Dr. Younis Kazim, CEO of Dubai Healthcare Corporation, Dubai Health Authority; Mansoor Al Malik, Executive Director for Policies and Legislation Division at Dubai Custom; Dr. Shamsa bin Hammad, Director of Dubai Corporation for Ambulance Services; and Waleed Al Sheibani, Director of Dubai Municipality Club. H.E. Yousef Abdullah Al Batran, Board Member of the UAE Jiu-Jitsu Federation, stressed that the championship is an important platform for discovering and nurturing talent across different age groups. 'The Khaled bin Mohamed bin Zayed Jiu-Jitsu Championship provides athletes with an ideal opportunity to develop their skills in a professional and competitive environment, while instilling values of discipline, confidence, and commitment. We are confident that the athletes will give their best in a championship that carries such a prestigious name, raising the level of competition and fulfilling the goals of the tournament,' he said. H.E. Mishaal Jalfar, CEO of Dubai Corporation for Ambulance Services, added, 'We are delighted to be present at such a major event. The importance of jiu-jitsu is clear, not only in promoting self-confidence, determination, and perseverance, but also in its diverse physical benefits. Today we witnessed an impressive crowd and excellent organisation, reflecting the sport's rising popularity and the strong support it enjoys across the UAE.' Javid Mohammadzadeh, father of Javad Mohammadzadeh, a Sharjah Self-Defence Sports Club athlete competing in the under-16 60 kg category, said, 'Javad has been practising jiu-jitsu for many years. He chose the sport himself and has a deep passion for it, dedicating long hours to training. Competing in such an important championship gives him a chance to learn, grow, and test himself against athletes of different levels.' The event concludes tomorrow with competitions in the under-18, adult, and master categories.
The Australian
28-07-2025
- Business
- The Australian
ADMA recruits Tom Goodwin to shake up committee
Futurist and global marketing provocateur Tom Goodwin has been appointed to the Association for Data-Driven Marketing and Advertising (ADMA) as the body's first internationally based member of its advisory committee (AAC). ADMA said the move aimed to 'broaden the perspectives and specialisms' with the AAC to help its members with 'future-focused capability building, progressive regulatory reform and leadership that actively shapes the future of marketing'. His appointment will also bring international insights and perspective, in a move that reflects the increasingly global nature of the marketing ecosystem. However, the move also signals an appetite for change for the organisation, which has struggled in recent years to capture the relevancy of other industry bodies. Mr Goodwin's appointment to the advisory committee follows the appointment of marketing veteran David Morgan as the chair of the AAC in April. Mr Morgan, whose career includes senior marketing roles with Procter & Gamble, Samsung, Citibank, Nestle and Standard Chartered, is the first new chair in a decade for ADMA and a sign that the organisation is looking for a shake-up. Mr Goodwin's appointment is further confirmation that ADMA is evolving. Mr Goodwin has built a strong international reputation for disruptive opinions and practical viewpoints. He told The Australian that he aimed to help 'lost' marketers navigate an industry in the throes of immense change and upheaval. 'I do think that marketers around the world are a little bit lost,' Mr Goodwin said. 'I think they're sold a narrative that everything they've done before is wrong and AI is going to take their job and that everything is different now. They're told that the skills they have are no longer relevant and I think that the role that ADMA has in providing leadership and stewardship is important.' 'The magical thing about marketing is we're actually really important. It's quite an odd thing to say, but we forget that we're helpful to people. We forget that we give people confidence in the decisions they make. We make people feel better and more confident in the holiday that they choose to go on, or the baked beans they buy. 'The reality is that the majority of what we do hasn't changed that much. And I think [marketers] are terrified by the fact that it doesn't need to be as hard as we think it has to be and that common sense and empathy will get us quite far.' With the immense focus on the impact of AI dominating all conversations, Mr Goodwin said marketers should remember that it was not their job to be a tech expert and they should focus on ensuring that they understood enough. 'It's all of our jobs to know quite a lot about AI, to experiment with AI and be thoughtful and curious, but it's not our job to the expert,' he said. '[Marketers] don't need to know whether Google vo3 is better than Mid journey's latest update. It's our job to have the right altitude and then to pull in expertise and know when to say no, when things aren't ready yet, when we should learn more, and ultimately, when to take a step back and ask, is this good?' Mr Goodwin is a proponent on the value of stepping back to gain perspective and view the full picture. It's a view being embraced by ADMA as the marketing organisation prepares to double-down on marketing's importance in driving strategic business growth. Danielle Long Editor, The Growth Agenda Danielle Long is the editor of The Growth Agenda. She joined The Australian in 2024 after two decades covering the marketing, media and advertising industry for specialist publications in Australia, Asia and the UK. The Growth Agenda Rideshare brand DiDi has launched a provocative advertising campaign as it aims to take on Uber and grow its share of the market. The Growth Agenda The impact of AI on the advertising and marketing industry is an opportunity for the market to get back to what it does best: creativity, according to WPP global creative chief Rob Reilly.
Yahoo
03-07-2025
- Business
- Yahoo
Exploring Three High Growth Tech Stocks In The US Market
Over the last 7 days, the United States market has risen 2.7% and is up 13% over the last 12 months, with earnings forecasted to grow by 15% annually. In this environment of robust growth, identifying high-growth tech stocks involves looking for companies that demonstrate strong innovation and adaptability in an ever-evolving landscape. Name Revenue Growth Earnings Growth Growth Rating Super Micro Computer 24.99% 39.09% ★★★★★★ Mereo BioPharma Group 53.64% 66.60% ★★★★★★ Ardelyx 21.03% 60.42% ★★★★★★ TG Therapeutics 26.46% 38.75% ★★★★★★ Legend Biotech 26.68% 57.96% ★★★★★★ AVITA Medical 27.42% 61.05% ★★★★★★ Alnylam Pharmaceuticals 23.69% 60.42% ★★★★★★ Alkami Technology 20.53% 76.67% ★★★★★★ Ascendis Pharma 35.07% 59.92% ★★★★★★ Lumentum Holdings 22.99% 103.97% ★★★★★★ Click here to see the full list of 226 stocks from our US High Growth Tech and AI Stocks screener. Here's a peek at a few of the choices from the screener. Simply Wall St Growth Rating: ★★★★☆☆ Overview: ADMA Biologics, Inc. is a biopharmaceutical company that develops, manufactures, and markets specialty plasma-derived biologics for treating immune deficiencies and infectious diseases globally, with a market cap of approximately $4.20 billion. Operations: ADMA focuses on developing and marketing plasma-derived biologics, primarily generating revenue from its Biomanufacturing segment, which accounts for $449.41 million, while its Plasma Collection Centers contribute $9.83 million. ADMA Biologics, having recently become profitable, exhibits a promising trajectory with its earnings expected to surge by 21.6% annually. This growth outpaces the broader US market's forecast of 14.7%. The firm's commitment to innovation is underscored by a recent FDA approval for a production process that boosts yields by 20%, significantly enhancing operational efficiency. Moreover, ADMA has initiated a robust share repurchase program valued at $500 million, reflecting confidence in its financial health and future prospects. These strategic moves, coupled with revenue projections rising to over $625 million by 2026, position ADMA well within the biotech sector's competitive landscape. Click here and access our complete health analysis report to understand the dynamics of ADMA Biologics. Evaluate ADMA Biologics' historical performance by accessing our past performance report. Simply Wall St Growth Rating: ★★★★☆☆ Overview: Aurinia Pharmaceuticals Inc. is a biopharmaceutical company focused on providing therapies for autoimmune diseases with significant unmet needs and has a market cap of $1.08 billion. Operations: Aurinia Pharmaceuticals generates revenue primarily through the research, development, and commercialization of therapeutic drugs, amounting to $247.30 million. Aurinia Pharmaceuticals has recently demonstrated a robust growth trajectory, with revenue forecasted to grow at 12.2% annually, outpacing the US market's average of 8.8%. This growth is complemented by an impressive expected annual earnings increase of 25.8%, signaling strong operational efficiency and market confidence. The company's strategic focus on R&D is evident from its significant investment, which has facilitated innovative treatments in lupus nephritis—highlighted by recent successful clinical results that are poised to enhance patient outcomes and potentially alter therapeutic standards in the industry. Furthermore, Aurinia's proactive approach to capital management is underscored by its recent share repurchases totaling $108.28 million, reinforcing its commitment to shareholder value amidst expanding market presence. Navigate through the intricacies of Aurinia Pharmaceuticals with our comprehensive health report here. Learn about Aurinia Pharmaceuticals' historical performance. Simply Wall St Growth Rating: ★★★★☆☆ Overview: ADTRAN Holdings, Inc. is a company that offers networking and communications platforms, software, systems, and services across the United States, Germany, the United Kingdom, and internationally with a market capitalization of approximately $711.86 million. Operations: ADTRAN Holdings generates revenue primarily through its Network Solutions segment, contributing $759.91 million, and its Services & Support segment, which adds $184.38 million. ADTRAN Holdings is distinguishing itself in the high-growth tech landscape, particularly through its recent deployment of FSP 3000 open optical transport technology. This innovation not only enhances data center interconnect capabilities for Cegeka but also integrates advanced security features like ConnectGuard™ optical-layer encryption and real-time fiber monitoring, ensuring high-capacity and reliable data transport. Furthermore, ADTRAN's strategic focus on R&D is evidenced by its significant annual investment in this area, aligning with industry trends towards more secure and scalable network solutions. With a revenue growth rate of 10.8% per year outpacing the US market average of 8.8%, and an impressive forecasted earnings growth of 107.3% annually, ADTRAN is well-positioned to capitalize on increasing demands for sophisticated networking solutions in various sectors including telecom and defense. Click here to discover the nuances of ADTRAN Holdings with our detailed analytical health report. Gain insights into ADTRAN Holdings' past trends and performance with our Past report. Discover the full array of 226 US High Growth Tech and AI Stocks right here. Are any of these part of your asset mix? Tap into the analytical power of Simply Wall St's portfolio to get a 360-degree view on how they're shaping up. Join a community of smart investors by using Simply Wall St. It's free and delivers expert-level analysis on worldwide markets. Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. Find companies with promising cash flow potential yet trading below their fair value. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include ADMA AUPH and ADTN. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
25-06-2025
- Business
- Yahoo
ADMA vs Takeda: Which Plasma Therapy Stock Is the Better Buy Today?
ADMA Biologics ADMA and Takeda TAK are leading players in the plasma derived immunoglobulin sector. ADMA markets plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases. On the other hand, Takeda has a well-diversified business with a focus on gastroenterology (GI), rare diseases, plasma-derived therapies (PDT), oncology and neuroscience. Given the companies' commanding position in the plasma-derived therapies market, choosing one stock over another can be challenging. Let us delve into their fundamentals, potential growth prospects, challenges and valuation levels to make a prudent choice. ADMA Biologics markets plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases. The company's top line currently comprises sales of three FDA-approved products — Bivigam (an Intravenous Immune Globulin ['IVIG'] product to treat primary humoral immunodeficiency), Asceniv (to treat primary immunodeficiency disease or PIDD) and Nabi-HB (to treat and provide enhanced immunity against the hepatitis B virus). Asceniv, its lead product, is a plasma-derived IVIG that contains naturally occurring polyclonal antibodies. These antibodies are proteins used by the body's immune system to neutralize microbes, such as bacteria and viruses, and prevent infections and diseases. Asceniv is indicated for the treatment of PIDD or inborn errors of immunity in adults and adolescents. It is manufactured using ADMA's unique, patented plasma donor screening methodology and tailored plasma pooling design, which blends normal source plasma with respiratory syncytial virus plasma obtained from donors tested using the company's proprietary microneutralization assay. Demand was record high in the first quarter. Consequently, ADMA expects Asceniv's total revenue share to expand throughout 2025 and beyond. ADMA plans to file a supplemental biologics license application in mid-2025 for the expansion of Asceniv's label to include the pediatric setting for patients who are two years and older. ADMA expects to generate initial, proof-of-concept animal data before 2025-end for its lead pipeline program, SG-001, a hyperimmune globulin targeting S. pneumonia. It believes that SG-001 has the potential to generate $300-500 million or more in high-margin annual revenues, with IP protection through at least 2037. Takeda is focused on developing life-saving plasma-derived therapies, which are essential for patients with a variety of rare and complex chronic diseases. Takeda has created a dedicated PDT business unit that manages the business end-to-end, from plasma donation to manufacturing, R&D and commercialization. The PDT business posted 9% growth in 2024. Takeda's broad immunoglobulin portfolio includes Hyqvia, Cuvitru, Gammagard Liquid and Gammagard S/D. Among these, Hyqvia is a product consisting of human normal IG and recombinant human hyaluronidase (licensed from Halozyme). Hyqvia is the only subcutaneous IG treatment for primary immunodeficiencies (PID) patients with a dosing regimen that requires only one infusion up to once per month and one injection site per infusion to deliver a full therapeutic dose of IG. It is approved in the United States for adults with PID, and in Europe for patients with PID syndromes and myeloma or CLL with severe secondary hypogammaglobulinemia and recurrent infections. Hyqvia was also approved for maintenance treatment in adult patients with chronic inflammatory demyelinating polyneuropathy (CIDP) in the United States and CIDP patients of all ages in Europe. Gammagard Liquid/Kiovig is a liquid formulation of the antibody replacement therapy immunoglobulin (IG), for the treatment of adult and pediatric patients two years of age or older with PID and adult patients with multifocal motor neuropathy (MMN) (administered intravenously). It is also approved for adult patients with CIDP. Kiovig is the brand name used for Gammagard Liquid in many countries outside the United States. Cuvitru is indicated as replacement therapy for primary humoral immunodeficiency in adults and pediatric patients two years of age and older. The PDT business is one of the focal areas for Takeda's R&D efforts. The company is developing next-generation immunoglobulin products with 20% facilitated SCIG (TAK-881) and liquid low IgA IG (TAK-880). It is also pursuing other early-stage opportunities (e.g., hypersialylated Immunoglobulin [hsIgG]) that would diversify its portfolio further. The company has also joined forces with Halozyme, Kamada, and Johnson & Johnson to advance its pipeline further. The Zacks Consensus Estimate for ADMA's 2025 sales implies a year-over-year increase of 18.61%, and that for earnings per share (EPS) suggests an improvement of 36.73%. However, EPS estimates for 2025 have moved south in the past 60 days. Nonetheless, the metric for 2026 has moved north during the same time frame. Image Source: Zacks Investment Research The Zacks Consensus Estimate for TAK's 2025 sales implies a year-over-year decrease of 2.80%, while that for EPS suggests an improvement of 6.21%. However, EPS estimates for 2025 and 2026 have moved south in the past 60 days. Image Source: Zacks Investment Research From the perspective of price performance, TAK has fetched better returns than ADMA so far this year. Shares of ADMA have gained 4.1%, while those of TAK have risen 13.91%. Image Source: Zacks Investment Research From a valuation standpoint, ADMA is more expensive than TAK. ADMA's shares currently trade at 21.79X forward earnings, higher than 9.03X for TAK. Image Source: Zacks Investment Research Large biotech companies are generally considered safe havens for investors interested in this sector. Takeda is a drug giant with an extremely broad and diverse portfolio. It is one of the three largest producers of plasma derivatives in terms of total sales. TAK's diversified plasma drug portfolio, global infrastructure, and encouraging R&D efforts should help it drive growth in its PDT business. TAK currently carries a Zacks Rank #4 (Sell). On the other hand, ADMA's top line is witnessing steady growth on the back of robust Asceniv demand. An acceleration in new patient starts, a potential label expansion and further penetration in existing markets should significantly expand Asceniv's sales. ADMA currently carries a Zacks #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. While large-cap TAK provides stability and has provided better returns than ADMA so far this year, we believe ADMA's revenue potential to be further unlocked with the market expansion of Asceniv, positioning it for solid growth. Hence, ADMA is a better pick at present. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report ADMA Biologics Inc (ADMA) : Free Stock Analysis Report Takeda Pharmaceutical Co. (TAK) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
Yahoo
24-06-2025
- Business
- Yahoo
ADMA Biologics (ADMA) Drops 14.7% W/W as 3 Execs Unload Portfolios
ADMA Biologics, Inc. (NASDAQ:ADMA) is one of the . ADMA Biologics fell by 14.7 percent week-on-week, closing Friday at $17.74 versus the $20.81 on June 13, as investors took path from three of its executives' recent disposition of shares in the company. In a regulatory filing, ADMA Biologics, Inc. (NASDAQ:ADMA) President and CEO Adam Grossman sold 21,000 ADMA shares at a price of $20.81 apiece on June 16 for a total value of $437,010. On the same day, he acquired 15,000 shares at a price of $5.4 apiece for a total of $81,000. ADMA Biologics, Inc. (NASDAQ:ADMA) said that the transaction was in line with the Rule 10b5-1 trading plan entered into between Grossman and Fidelity Brokerage Services LLC. The transaction followed sales activities made by the company's chairman, Steven Elms, and founder and vice chairman, Jerrold Grossman. For his part, Elms sold 425,621 of his shares in the company for an aggregate market value of $9.3 million, while Jerrold disposed of 10,000 shares at an aggregate market value of $206,100. An independent distributor in their pharmacy with a range of biopharmaceutical products on display. It is worth noting that ADMA Biologics, Inc.'s (NASDAQ:ADMA) closing price on Friday marked its sixth straight day of decline. While we acknowledge the potential of ADMA as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey.
